Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MND-2119 vs Epadel in Hypertriglyceridemia
NCT03693131Phase 3Completed
- Sponsor
- Mochida Pharmaceutical Co., Ltd.
- Start
- Oct 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Epadel in hypertriglyceridemia (4 arms), sponsored by Mochida Pharmaceutical Co., Ltd. Primary endpoint: Percentage of change from baseline in serum triglyceride level at 12 weeks. Started Oct 2018; status: completed.
02
Drugs
Epadel
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT03693131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03693131.